On May 20, 2025, the Department of Drug Administration - Ministry of Health issued Official Letter No. 1377/QLD-CL regarding the Alfachim 4.2 drug sample; No. GDKLH: VD-34573; No. batch: 0301062; Producer: 01/06/2024; HD: 01/06/2026 produced by Cuu Long Pharmaceutical Joint Stock Company not meeting quality standards on quantity and circulation in Hanoi.
On May 21, 2025, immediately after receiving instructions from the Drug Administration Department, Cuu Long Pharmaceutical Joint Stock Company issued Official Letter No. 1086/CV.DCL announcing the revocation of Alfachim 4.2 product No. GDKLH: VD-34573; Subject: 03010624; Producer: 01.6.2024; HD: 01.01.2026 to distributor units in Hanoi and businesses and users of drugs provided by Ngoc Khanh Pharmaceutical - Medical Supply Joint Stock Company (Coaster 312A, Floor 3, H Center - No. 1 Nguyen Huy Tuong, Thanh Xuan, Hanoi City).
The content of the notice has clearly stated the recovery process and the time limit for completion of this job is on 2.6.2025 across Hanoi. The recovery will be seriously implemented by Cuu Long Pharmaceutical Joint Stock Company and branch in Hanoi to seriously comply with the instructions of the Drug Administration as well as the current law.
Along with that, Cuu Long Pharmaceutical Joint Stock Company urgently conducted a review of the entire production process, quality inspection and product distribution. On May 26, 2025, Cuu Long Pharmacy also sent Official Letter 244/CV.DCL to the Drug Administration of Vietnam - Ministry of Health; Central Drug Testing Institute; Ho Chi Minh City Drug Testing Institute; The Department of Health of Vinh Long Province to report in detail the production situation (production quantity, supply quantity, expiry date, date of production, registration number, lot number, active ingredient name) and the distribution of drug lots (name and address of the business have purchased drugs, quantity purchased and inventory).
Currently, Dai Cuu Long is closely coordinating with authorities to find out the cause of the incident. In the immediate future, it is necessary to coordinate to conduct additional samples at business establishments to check the quality of the qualitative indicators of these drug models, thereby having a basis to assess the subjective and objective causes that may affect product quality.
Cuu Long Pharmaceutical Joint Stock Company is committed to fully coordinating with the authorities and is ready to perform responsibilities as prescribed if the cause is determined from the production process or quality control of the company. While waiting for the official conclusion from the authorities, the company continues to conduct a comprehensive review of the quality management system, especially in the production and testing stage, considering this is an opportunity to strengthen and further improve the quality standards - the platform has created the prestige of the last 50 years of Cuu Long Pharmacy.
A representative of Cuu Long Pharmaceutical said that the company understands that reputation is the invaluable asset of a business, especially in the pharmaceutical - medical field. And that reputation must be built on product quality, transparency, and accuracy in system governance. Therefore, the company is committed to acting responsibly, measurably and resolutely to be worthy of the trust of customers, partners and the whole society.
With nearly 50 years of operation in the pharmaceutical field, Cuu Long Pharmaceutical Joint Stock Company has become a familiar name, prestigious with consumers, pharmacies and major hospitals in provinces and cities of Vietnam. Mekong Delta is committed to providing quality, safe and effective products.
With the efforts it has achieved, in recent years, the company has been honored to receive many prestigious awards such as: Second Class Labor Medal; Top 10 Trusted Consumer Products and Services; "Vietnam Drug Star" Award; Top 10 Famous Brands; Top 10 Leading Brands in Vietnam 2022; Top 10 prestigious Brands in Asia and many other prestigious awards.
